Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

被引：1
|
作者：
Saydan, Betuel [1 ]
Ozmen, Deniz [2 ]
Eskazan, Ahmet Emre [2 ]
机构：
[1] Ankara Univ, Fac Med, Ankara, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkiye
来源：
EXPERT REVIEW OF HEMATOLOGY | 2024年 / 17卷 / 07期
关键词：
Chronic myeloid leukemia; CML; dasatinib; low-dose; 50; mg; CHRONIC LYMPHOCYTIC-LEUKEMIA; DECISION-SUPPORT-SYSTEM; SURVIVAL; CLL; INCORPORATE; PREFERENCES; POPULATION; GUIDELINES; IBRUTINIB; LYMPHOMA;
D O I：
10.1080/17474086.2024.2370556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 277
页数：3
相关论文
共 50 条
  • [31] Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
    Klink, Andrew J.
    Keating, Scott J.
    Brokars, John
    Feinberg, Bruce
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03) : 149 - 157
  • [32] Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia
    周励
    China Medical Abstracts(Internal Medicine), 2013, 30 (02) : 123 - 123
  • [33] Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
    Wang, Jianxiang
    Shen, Zhi-Xiang
    Saglio, Giuseppe
    Jin, Jie
    Huang, He
    Hu, Yu
    Du, Xin
    Li, Jianyong
    Meng, Fanyi
    Zhu, Huanling
    Hu, Jianda
    Wang, Jianmin
    Hou, Ming
    Hertle, Sabine
    Menssen, Hans D.
    Ortmann, Christine-Elke
    Tribouley, Catherine
    Yuan, Ye
    Baccarani, Michele
    Huang, Xiaojun
    BLOOD, 2015, 125 (18) : 2771 - 2778
  • [34] First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
    Rea, D.
    Etienne, G.
    Nicolini, F.
    Cony-Makhoul, P.
    Johnson-Ansah, H.
    Legros, L.
    Huguet, F.
    Tulliez, M.
    Gardembas, M.
    Bouabdallah, K.
    Rousselot, P.
    Cayuela, J-M
    Guilhot, F.
    Mahon, F-X
    LEUKEMIA, 2012, 26 (10) : 2254 - 2259
  • [35] An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Luis Steegmann, Juan
    Colomer, Dolors
    Gomez-Casares, Maria-Teresa
    Garcia-Gutierrez, Valentin
    Orti, Guillermo
    Ramirez-Payer, Angel
    Olavarria, Eduardo
    Vall-llovera, Ferran
    Giraldo, Pilar
    Conde, Eulogio
    Vallansot, Rolando
    Luis Lopez-Lorenzo, Jose
    Palomera, Luis
    Alvarez-Larran, Alberto
    Conesa, Venancio
    Bautista, Guiomar
    Casas, Laura
    Giles, Frank
    Hochhaus, Andreas
    Felipe Casado-Montero, Luis
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (10) : 2059 - 2066
  • [36] Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
    Hjorth-Hansen, H.
    Stentoft, J.
    Richter, J.
    Koskenvesa, P.
    Hoeglund, M.
    Dreimane, A.
    Porkka, K.
    Gedde-Dahl, T.
    Gjertsen, B. T.
    Gruber, F. X.
    Stenke, L.
    Eriksson, K. M.
    Markevarn, B.
    Lubking, A.
    Vestergaard, H.
    Udby, L.
    Bjerrum, O. W.
    Persson, I.
    Mustjoki, S.
    Olsson-Stromberg, U.
    LEUKEMIA, 2016, 30 (09) : 1853 - 1860
  • [37] Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
    Gambacorti-Passerini, Carlo
    Piazza, Rocco
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (23) : 2274 - 2276
  • [38] Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
    Hochhaus, Andreas
    Wang, Jianxiang
    Kim, Dong-Wook
    Kim, Dennis Dong Hwan
    Mayer, Jiri
    Goh, Yeow-Tee
    le Coutre, Philipp
    Takahashi, Naoto
    Kim, Inho
    Etienne, Gabriel
    Andorsky, David
    Issa, Ghayas C.
    Larson, Richard A.
    Bombaci, Felice
    Kapoor, Shruti
    McCulloch, Tracey
    Malek, Kamel
    Yau, Lillian
    Ifrah, Sophie
    Hoch, Matthias
    Cortes, Jorge E.
    Hughes, Timothy P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [39] Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
    Masarova, Lucia
    Cortes, Jorge E.
    Patel, Keyur P.
    O'Brien, Susan
    Nogueras-Gonzalez, Graciela M.
    Konopleva, Marina
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    Ravandi-Kashani, Farhad
    Borthakur, Gautam
    DellaSala, Sara
    Estrov, Zeev
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    CANCER, 2020, 126 (07) : 1448 - 1459
  • [40] Dasatinib Dose Management for the Treatment of Chronic Myeloid Leukemia
    Talpaz, Moshe
    Saglio, Giuseppe
    Atallah, Ehab
    Rousselot, Philippe
    CANCER, 2018, 124 (08) : 1660 - 1672
12345